Subscribe
shutterstock_1349383838_thomas_quack
Thomas Quack / Shutterstock.com
22 October 2019AmericasSarah Morgan

CRISPR Therapeutics to buy JV from Bayer

A joint venture between gene-editing startup CRISPR Therapeutics and German pharmaceutical company Bayer will come under the control of CRISPR Therapeutics, according to the pair’s proposed plans.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Bayer and CRISPR close joint venture transaction
19 August 2016   Bayer has launched a partnership with CRISPR Therapeutics.


Editor's picks

Why US patent reform is ‘essential’ for US economic prosperity and security
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025

Editor's picks

Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025

More on this story

Americas
Bayer and CRISPR close joint venture transaction
19 August 2016   Bayer has launched a partnership with CRISPR Therapeutics.

More on this story

Americas
Bayer and CRISPR close joint venture transaction
19 August 2016   Bayer has launched a partnership with CRISPR Therapeutics.

More features

UPC orders 17-country ban on EOFlow's pumps in Insulet feud
US warns of rising counterfeit drug threat from India and China
Judge denies Pfizer and BioNTech bid to see off COVID-19 vaccine suit
Biotech and healthcare expert returns to Latham & Watkins
AstraZeneca to appeal invalidated diabetes patent in generics dispute
Why US patent reform is ‘essential’ for US economic prosperity and security
Medical company sees $452m trade secrets award cut by 87%
Fed Circ: Generic doesn’t infringe Metacel MS drug